Skip to content

Generalized Anxiety Therapy Effectiveness

Clinical Effectiveness of Digital CBT for the Treatment of Generalized Anxiety Disorder: A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05748652
Acronym
GATE
Enrollment
351
Registered
2023-03-01
Start date
2023-03-06
Completion date
2024-02-28
Last updated
2024-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Anxiety Disorder

Keywords

Generalized Anxiety Disorder, GAD, anxiety, digital CBT

Brief summary

This study will examine the effectiveness of digital CBT versus psychoeducation in improving anxiety for those with Generalized Anxiety Disorder.

Detailed description

This study aims to examine the effectiveness of app-based digital CBT for anxiety compared to psychoeducation in individuals with a diagnosis of Generalized Anxiety Disorder. The primary outcomes are anxiety symptom reduction and remission after 10 weeks.

Interventions

An app-based intervention based on principles from cognitive behavioral therapy for anxiety.

OTHERPsychoeducation

Participants will be provided with psychoeducation which will be delivered digitally upon allocation to the psychoeducation arm.

Sponsors

Boston University
CollaboratorOTHER
Big Health Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults aged ≥22 years old * Score ≥15 on the 7-item Generalized Anxiety Disorder questionnaire (GAD-7) * Diagnosis of GAD * Current resident of the USA * Oral and written fluency in English * Regular access to the internet via a mobile or tablet device using Android ( 8 or higher) or iOS (13 or higher) * Participant is able and willing to comply with protocol requirements, has been informed of the nature of the study, and has signed the IRB-approved informed consent form

Exclusion criteria

* Must not be currently receiving or be expecting to start psychological treatment for anxiety during study participation, or have previously received Cognitive Behavioral Therapy (CBT) or Acceptance and Commitment Therapy (ACT) for anxiety in the past 6-months (self-report) * If on psychotropic medication, this must be stable for at least 60 days * Past or present psychosis, schizophrenia, or bipolar disorder, or current OCD * Past 12 months alcohol or substance use disorder of moderate or greater severity * Moderate or greater suicide risk * Hearing or vision impairment that prevents effective use of the audio-visual content of digital CBT or psychoeducation * Intellectual disability or any Neurocognitive or Neurodevelopmental disorder that would prevent participants from following study procedures * Any condition that the investigator believes would make participation in the study not in the best interest of the subject or would preclude successful completion of study activities

Design outcomes

Primary

MeasureTime frameDescription
Generalized Anxiety Disorder Questionnaire (GAD-7)10 weeks post-randomizationValidated questionnaire; a 7-item scale with total scores between 0 and 21 where higher scores indicate greater severity
Generalized Anxiety Disorder remission (score 1 or 2) on the the Clinical Global Impression Scale - Improvement (CGI-I)10 weeks post-randomizationA single-item measure scored between 1 and 7 where scores of 1 or 2 indicates clinically significant improvement, a score of 3 indicates mild improvement, a score of 4 indicates no change, and scores from 5 to 7 indicate deterioration

Secondary

MeasureTime frameDescription
Patient Health Questionnaire (PHQ-8)Weeks 10 and 24 post-randomizationValidated questionnaire; an 8-item scale with total scores between 0 and 24 where higher scores indicate greater severity
Generalized Anxiety Disorder Questionnaire (GAD-7)6 and 24 weeks post-randomizationValidated questionnaire; a 7-item scale with total scores between 0 and 21 where higher scores indicate greater severity
Clinical Global Impression - Severity (CGI-S)Weeks 10 and 24 post-randomizationA single-item measure scored between 1 and 7 where higher scores indicate greater severity of Generalized Anxiety Disorder Symptoms
Sleep Condition Indicator (SCI-8)Weeks 10 and 24 post-randomizationValidated questionnaire; an 8-item scale with total scores between 0 and 32 where higher scores indicate better sleep
Generalized Anxiety Disorder remission (score 1 or 2) on the the Clinical Global Impression Scale - Improvement (CGI-I)24 weeks post-randomizationA single-item measure scored between 1 and 7 where scores of 1 or 2 indicates clinically significant improvement, a score of 3 indicates mild improvement, a score of 4 indicates no change, and scores from 5 to 7 indicate deterioration

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026